Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

NIAID Data Ecosystem2026-03-12 收录

结直肠癌肝转移治疗

免疫联合化疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2381660 数据链接链接失效反馈

官方服务：

资源简介：

This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis and pMMR/MSS status.

创建时间：

2021-06-15

Supplementary Material for: Long-term and sustained remission of advanced triple-negative breast cancer with large chest wall lesions after transient chemoimmunotherapy: a case report

三阴性乳腺癌治疗

免疫联合化疗

Abstract Introduction: Herein, we reported a case of advanced triple-negative breast cancer (TNBC) with special clinical manifestations that achieved durable remission after short-term application of

DataCite Commons2025-01-03 更新70

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

结直肠癌肝转移治疗

肝动脉灌注化疗

Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A dev

NIAID Data Ecosystem60

Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter study

结直肠癌肝转移治疗

生存率评估

Primary objectives: Taux de survie sans progression à 9 mois selon RECIST 1.1. Primary endpoints: Le critère de jugement principal sera d’évaluer la proportion de patients vivants sans progression (le

NIAID Data Ecosystem40

Phase I/II Trial of Bevacizumab in Combination With FOLFOXIRI As First-Line Therapy in Colorectal Cancer Patients With Liver Metastases

结直肠癌肝转移治疗

肿瘤临床试验

Interventions: Treatment is administered every 2 weeks until evidence of DLT, progression, unacceptable toxicity, patient refusal, or for a maximum of 2 cycles to assess the feasibility. (phase I) Tre

NIAID Data Ecosystem60

Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases

结直肠癌肝转移治疗

靶向治疗疗效

Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with

NIAID Data Ecosystem50

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

资源简介：

相关数据集